Early results from 19 patients treated in the Boston clinical trial show that Endostatin is safe and well-tolerated in high doses without any evidence of toxicity. Extended periods of stable disease and minor responses have been demonstrated, but further study is needed to determine its long-term effectiveness.
Researchers found that combining radiation therapy with androgen suppression therapy significantly reduced the risk of PSA failure in men with intermediate- and high-risk prostate cancer. The treatment showed efficacy even in low-risk patients, suggesting a potential benefit for all early-stage prostate cancer patients.
A new study finds that the 'cell crisis' theory explains why certain cancers become more common with age. Genetic mutations cause cells to divide uncontrollably after telomeres shorten, leading to cancer development.
Researchers at Dana-Farber Cancer Institute have charted the chain of events by which estrogen receptor-negative (ER-negative) breast cancer cells are formed. By understanding this process, scientists can identify potential targets for specific therapies to stop ER-negative tumors from growing.